|
Categories |
|
Central Nervous System |
|
|
Biotechnology
Cancer
Consumer
Customer
Relationship Management
Drug
Delivery
eHealthcare
Pharma
eHealthcare
Physician
Generics
Healthcare
Medical
Devices
OTC
Pharmaceuticals
Pharmaceuticals
Pharmacoeconomics
Therapeutic
Areas:
- Cardiovascular
- Central
Nervous System
- Immune
Disorders and Inflammation
- Infectious
Diseases
- Oncology
-
Women'sHealth
|
|
|
1- Pipeline and Commercial Insight: Alzheimer’s Disease - Beta treatments on the horizon 07-Nov-2005
Detailed analysis of the commercial opportunities and threats facing Alzheimer's disease therapeutics across the seven major markets, including a review of the late-stage development pipeline and sales forecasts for key drugs.
------------------------------------------------------------------------------------------------------------------------- |
2- The CNS Market Outlook to 2010 05-Oct-2005
------------------------------------------------------------------------------------------------------------------------- |
3- Stakeholder Insight: Cognitive Impairment in Schizoaffective Disorder - Inevitable or Treatable? 04-Oct-2005
Detailed analysis of prescribing trends in cognitive impairment in schizophrenia (CIS) across the seven major pharmaceutical markets. Identifies stakeholder relationships and key unmet needs in diagnosis and treatment, and patient management.
------------------------------------------------------------------------------------------------------------------------- |
4-Tysabri - Can Efficacy of VLA-4 Mechanism Overcome Safety Concerns? 05-Oct-2005
Overview of the withdrawal of Tysabri (natalizumab) from the multiple sclerosis market in February 2005, and discussion of the potential relaunch of the drug, supported by key opinion leader interviews.
------------------------------------------------------------------------------------------------------------------------- |
5- Commercial Insight: ADHD - Strattera Will Reign Supreme When Branded Stimulants Slump 22-Jul-2005
In-depth analysis of the ADHD market with forecasts of all leading products on a country-by-country basis for the seven major pharmaceutical markets until 2015.
------------------------------------------------------------------------------------------------------------------------- |
6- Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail to Nail Neuropathic Pain 18-Jul-2005
Detailed analysis of the neuropathic pain pipeline, including an assessment of the latest trial data and clinical strategies. Includes an indication specific ten-year forecast for future key products.
------------------------------------------------------------------------------------------------------------------------- |
7- Top CNS Portfolios in 2004 - The Industry Gold
Standards 6-Jan-2005
Analysis of the highlights of the leading CNS
portfolios in 2004.
-------------------------------------------------------------------------------------------------------------------------
|
8- Commercial Insight: Migraine - A Painful Future for
the Triptans? 22-Dec-
2004
An
in-depth analysis of the migraine market with particular focus on
the triptans, providing forecasts of leading products on a
country-by-country basis for the seven major pharmaceutical markets
until 2014.
-------------------------------------------------------------------------------------------------------------------------
|
9- Commercial Insight: Antipsychotics - From Blockbuster
Brands to Billion Dollar Generics
22-Dec- 2004
An in-depth analysis of the antipsychotics market with
forecasts of all leading products on a country-by-country basis for
the seven major pharmaceutical markets until
2014.
-------------------------------------------------------------------------------------------------------------------------
|
10- Patient Compliance in Psychiatry - From Patient
Acquisition to Patient Retention
15-Dec- 2004
Analysis of patient compliance in psychiatry based on
an international survey of 192 therapists and leading experts
conducted across the seven major pharmaceutical
markets.
-------------------------------------------------------------------------------------------------------------------------
|
11- Restless Legs Syndrome - Recognition Lacking
Still 8-Nov- 2004
An overview of the
epidemiology, treatment, unmet needs, and market opportunities in
the restless legs syndrome market.
-------------------------------------------------------------------------------------------------------------------------
|
12- Pipeline Insight: Nociceptive Pain - Safety Profile
Uppermost in Crowded Market 21-Oct-
2004
Comprehensive insight into nociceptive pain, the
market's unmet needs, and its treatment pipeline. It includes
profiles of compounds being developed and revenue forecasts to 2014,
using Datamonitor's forecasting
methodology.
-------------------------------------------------------------------------------------------------------------------------
|
13- Insomnia - Wake-Up Call for a Sleepy
Market 13-July-
2004
Provides an overview of insomnia market and identifies
the current market leaders and forecasts sales to 2012. Primary
contenders for entrance in to the market and lifecycle management of
current products are evaluated.
------------------------------------------------------------------------------------------------------------------------- |
14-
Alzheimer's Disease - Diagnosis, Disease Modification
and Prevention Key to Growing Market 02-July-2004
Comprehensive insight
into Alzheimer's disease, the market's unmet needs, and its
treatment pipeline.
------------------------------------------------------------------------------------------------------------------------- |
15- Commercial Perspectives: Multiple Sclerosis - How to
Find Opportunities in an Unremitting Market 17-Jun-2004
An in-depth analysis of the multiple sclerosis market
with detailed profiles of all leading products.
------------------------------------------------------------------------------------------------------------------------- |
16- Stakeholder Insight: Neuropathic Low Back Pain -
Off-label Revenue Despite Diagnostic Challenge 3-June-2004
A detailed treatment analysis of Neuropathic Low back
pain, based on extensive interviews with primary care physicians,
pain specialists, surgeons, neurologists, and opinion leading
physicians from 7 major pharmaceutical markets.
-------------------------------------------------------------------------------------------------------------------------
|
17- Stakeholder Insight: HIV Related Neuropathic Pain -
Useful Niche for Peripheral Companies 03-May-2004
A detailed treatment analysis of HIV-related
neuropathic pain, based upon 171 interviews with primary care
physicians, pain specialists, surgeons, neurologists, and opinion
leading physicians from five major pharmaceutical markets.
-------------------------------------------------------------------------------------------------------------------------
|
18- Postoperative Pain: Dynastat Cutting Up The Pain
Market 19-Apr-2004
An overview of the
epidemiology, treatment, unmet needs, and market opportunities in
the postoperative pain market.
------------------------------------------------------------------------------------------------------------------------- |
19-
Stakeholder Insight: Fibromyalgia - Substantial Growth
Opportunity for SNRI Antidepressants 19-Mar-2004
Fibromyalgia is a relatively common chronic pain
syndrome, affecting around 2% of the population. This little
understood market suffers from high unmet need both at the level of
drug research and current clinical practice.
-------------------------------------------------------------------------------------------------------------------------
|
20-
Adult ADHD - Strattera Grows
Up 18-Mar-2004
Provides an overview of adult ADHD and identifies the
current market leaders and forecasts sales in this emerging market.
Primary contenders for entrance in to the market and lifecycle
management of current products are evaluated.
-------------------------------------------------------------------------------------------------------------------------
|
21- Stakeholder Insight: Anxiety Disorders - More Than
Just a Comorbidity
18-Mar-2004
An in-depth analysis of treatment practices of anxiety
disorder across the seven major
markets.
-------------------------------------------------------------------------------------------------------------------------
|
22- Stakeholder Insight: Neuropathic Pain - Comparative
Overview of Treatment Preferences Across the Seven Major
Markets
5-Mar-2004
Use this
report to gain a better understanding of the challenges faced by
existing and future players in the neuropathic pain
market.
-------------------------------------------------------------------------------------------------------------------------
|
23- Neuropathic Pain Insight - Life Beyond Gabapentin
25-Feb-2004
The current neuropathic pain market suffers from lack
of public awareness, poor physician education (often leading to
misdiagnosis), under-utilization of effective drugs, inappropriate
use of medications, and regional variations in drug
availability.
-------------------------------------------------------------------------------------------------------------------------
|
24- Stakeholder Insight: Bipolar Disorders - Zyprexa Sets
the Mood for Revenue Growth
11-Feb-2004
Detailed analysis of prescribing trends in bipolar
disorder by specific episode, across the seven major pharmaceutical
markets. Identifies stakeholder relationships and key unmet needs in
diagnosis and treatment and patient
management.
-------------------------------------------------------------------------------------------------------------------------
|
25- Commercial Insight: Antidepressants - Sliding SSRI
Revenues Inevitable
6-Feb-2004
An in-depth analysis of the antidepressant market with
detailed profiles of all leading products.
-------------------------------------------------------------------------------------------------------------------------
|
26-
The Outlook for Niche CNS Disorders: Commercial
opportunities in developing markets Feb-2004
This report
will evaluate the best areas for investment in each niche CNS market
and will also identify future leaders. Penetrating niche markets is
often a cost-effective way to access larger indications (since
safety and tolerability can be proved in smaller trials) and/or to
benefit from off-label sales in related indications.
-------------------------------------------------------------------------------------------------------------------------
|
27- Stakeholder Opinions: Migraine - Lots of Experience,
But Less Expertise
30-Jan-2004
A review
of triptans, ergotamines, and other therapeutic options used for
both acute and prophylactic treatment of
migraine.
-------------------------------------------------------------------------------------------------------------------------
|
28- Pipeline Insight: Antipsychotics - Novel
Antipsychotics Driving Market Evolution 13-Nov-2003
In-depth
analysis of the antipsychotic drug
pipeline.
-------------------------------------------------------------------------------------------------------------------------
|
29- The CNS Market Outlook to 2008 Nov- 2003
Identify potential growth areas within key CNS markets
(including Alzheimer's disease, depression, epilepsy, migraine,
multiple sclerosis, pain, Parkinson's disease and schizophrenia) for
your company and develop revenue yielding strategies with this new
management
report.
-------------------------------------------------------------------------------------------------------------------------
|
30- Amyotrophic Lateral Sclerosis: A route to larger CNS
markets? 3-Oct-2003
For this
analysis, Datamonitor interviewed key opinion leaders to provide
insight into clinical, regulatory, and environmental issues
affecting the amyotrophic lateral sclerosis (ALS)
market.
-------------------------------------------------------------------------------------------------------------------------
|
31- Pipeline Insight: Depression - Novel therapies key to
market penetration 15-Sep-2003
Several
leading antidepressant brands are expecting patent expiries over the
next five years. New strategies are needed to prevent a decline in
this multi billion dollar market. This report provides in depth
analysis of the depression drug
pipeline.
-------------------------------------------------------------------------------------------------------------------------
|
32- Commercial Perspectives: Sleep Disorders -
Insomnia, Narcolepsy & Restless Leg Syndrome 22-Aug-2003
New
opportunities for future growth, with valuable insight from opinion
leader interviews.
-------------------------------------------------------------------------------------------------------------------------
|
33- Rapid Cycling Bipolar Disorder: Another niche
indication? 21-Aug-2003
Rapid
cycling bipolar disorder is a market with many unmet needs, although
barriers to entry are high. Pharmaceutical manufacturers need to
invest substantial money into clinical trials to demonstrate a
drug's efficacy .
-------------------------------------------------------------------------------------------------------------------------
|
34- Stakeholder Perspectives: Mild Cognitive Impairment
and Dementia - Aricept in race to pioneer unexplored markets
18-Aug-2003
Drug
manufacturers look beyond mild-to-moderate Alzheimer's
disease.
-------------------------------------------------------------------------------------------------------------------------
|
35- Prexige: Innovative Strategies To Ensure Commercial
Gain 8-Aug-2003
An
analysis of the clinical data, growth strategies, market positioning
and commercial opportunities for Novartis' Prexige, a new COX-II
inhibitor
product.
-------------------------------------------------------------------------------------------------------------------------
|
36- Menstrual Migraine - An opportunity to gain a
competitive advantage for triptan
manufacturers
5-Aug-2003
Market
opportunities, epidemiology, clinical data and growth strategies of
manufacturers.
-------------------------------------------------------------------------------------------------------------------------
|
37- Pipeline Insight: Anticonvulsants - Drug Versatility
Crucial for Market Success 15-July-2003
In depth analysis of the
anticonvulsant drug
pipeline.
-------------------------------------------------------------------------------------------------------------------------
|
38-
Medical Devices in CNS Disorders - Opportunities in
Developing Markets
13-Jun-2003
-------------------------------------------------------------------------------------------------------------------------
|
39- Duloxetine - The Next Blockbuster Antidepressant?
1-May-2003
------------------------------------------------------------------------------------------------------------------------- |
40- Treatment Algorithms: Major
Depressive Disorder, 4th Edition - Gaining Competitive Advantage in
a Mature Environment 18-Apr-2003
-------------------------------------------------------------------------------------------------------------------------
|
|
41- Behavioral Disorders - Opportunities To Shape Future
Markets 14-4-2003
------------------------------------------------------------------------------------------------------------------------
|
42- CNS Market Analysis 2002:
Commercial Viability of Four Dynamic CNS Markets
4-Apr-2003
-------------------------------------------------------------------------------------------------------------------------
|
43- Strategic Perspectives: Multiple Sclerosis - Antegren
to Challenge Beta-Interferons 4-Mar-2003
------------------------------------------------------------------------------------------------------------------------- |
44-
Strategic Perspectives: Commercial Opportunities in
Depression - Generating Revenue Growth In Symptoms And
Comorbidities 20-Jan-2003
------------------------------------------------------------------------------------------------------------------------- |
45- Pregabalin: Follow-On Strategy a Winner for
Pfizer 6-Jan-2003
------------------------------------------------------------------------------------------------------------------------- |
46- Strategic Perspectives: Attention Deficit
Hyperactivity Disorder - Strattera to Add Novel Dimension to the
Market 6-Jan-2003
------------------------------------------------------------------------------------------------------------------------- |
| |
| |
